1024 / 1578
/
/
SBRT for prostate cancer
Matthias Guckenberger - ESTRO SBRT Course 2017
3
Why SBRT
Why not SBRT
Small well circumscribed target
Risk of extracapsular extension
Low alpha / beta ratio
Really very low
Benefit of dose escalation
Only for bRFS
Technical solutions available
Lack of standardization
Strong competition
Should not be a reason per se
07.09.17
/
/
Use of SBRT for prostate cancer
Matthias Guckenberger - ESTRO SBRT Course 2017
4
07.09.17
National Cancer Data Base covering 70% of US cancer patients
Ø
SBRT for PCa under academic evaluation